Varespladib methyl has been investigated for the treatment of Acute Coronary Syndrome. Studies showed that Varespladib methyl treatment resulted in significant positive changes on lipoproteins and inflammation.
- Mechanism
- Curator reviewed
A–002 is an orally administered‚ potent inhibitor of secretory phospholipase spla2(spla2)‚ including groups IIA‚ V‚ and X. Atherosclerosis is a disease of the arteries that results from inflammation and the build-up of plaque under the lining of the blood vessel. This build-up can cause vascular swelling and eventual rupture. spla2 levels have been shown to be elevated in patients with both stable and unstable coronary artery disease. Higher levels of the enzyme have been shown to predict an increased risk for future cardiovascular events such as heart attacks and stroke.
- Primary indication
- Investigated for use/treatment in atherosclerosis and coronary artery disease.Curator reviewed
- Formula / weight
- C22H22N2O5 · 394.427 g/mol (avg)
- Also known as
- Varespladib methyl ester
- Code names
- A-002 · LY-333013 · S-3013
Resolves to
VJYDOJXJUCJUHL-UHFFFAOYSA-NSMILESCCC1=C(C(=O)C(N)=O)C2=C(OCC(=O)OC)C=CC=C2N1CC1=CC=CC=C1What you can answer from here — as of June 15, 2026
Which drugs share a target with Varespladib methyl, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account